ARTICLE

Received 1 Nov 2016 | Accepted 5 Apr 2017 | Published 26 May 2017

DOI: 10.1038/ncomms15518

OPEN

Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in *RAF1*-mutant Noonan syndrome

Jiani C. Yin^{1,2,3}, Mathew J. Platt⁴, Xixi Tian⁵, Xue Wu^{1,†}, Peter H. Backx⁵, Jeremy A. Simpson⁴, Toshiyuki Araki^{2,3} & Benjamin G. Neel^{1,2,3}

Noonan syndrome (NS) is caused by mutations in RAS/ERK pathway genes, and is characterized by craniofacial, growth, cognitive and cardiac defects. NS patients with kinase-activating *RAF1* alleles typically develop pathological left ventricular hypertrophy (LVH), which is reproduced in *Raf1*^{L613V/+} knock-in mice. Here, using inducible *Raf1*^{L613V} expression, we show that LVH results from the interplay of cardiac cell types. Cardiomyocyte *Raf1*^{L613V} enhances Ca²⁺ sensitivity and cardiac contractility without causing hypertrophy. *Raf1*^{L613V} expression in cardiomyocytes or activated fibroblasts exacerbates pressure overload-evoked fibrosis. Endothelial/endocardial (EC) *Raf1*^{L613V} causes cardiac hypertrophy without affecting contractility. Co-culture and neutralizing antibody experiments reveal a cytokine (TNF/IL6) hierarchy in *Raf1*^{L613V}-expressing ECs that drives cardiomyocyte hypertrophy *in vitro*. Furthermore, postnatal TNF inhibition normalizes the increased wall thickness and cardiomyocyte hypertrophy *in vivo*. We conclude that NS-cardiomyopathy involves cardiomyocytes, ECs and fibroblasts, TNF/IL6 signalling components represent potential therapeutic targets, and abnormal EC signalling might contribute to other forms of LVH.

¹ Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7. ² Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada M5G 1L7. ³ Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York 10016, USA. ⁴ Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1. ⁵ Department of Biology, York University, Toronto, Ontario, Canada M3J 1P3. † Present address: Geneseeq Technology Inc., Toronto, Ontario, Canada M5G 1L7. Correspondence and requests for materials should be addressed to J.A.P. (email: jeremys@uoguelph.ca) or to T.A. (email: toshiaki.araki@nyumc.org) or to B.G.N. (email: benjamin.neel@nyumc.org).

Pathological left ventricular hypertrophy (LVH) is a common inherited disorder (~1 in 500 live births), and represents the leading cause of sudden death in young people^{1–3}. Features of pathological hypertrophy include increased cardiomyocyte (CM) size, thickening of the ventricular wall and septum, perivascular and interstitial fibrosis, and cardiac dysfunction that can eventuate in heart failure^{2,3}. LVH has many potential etiologies, including hypertension, cardiac valve disease or genetic defects^{4–6}. Most inherited forms of LVH are caused by mutations in genes encoding sarcomeric proteins^{1,3,5,7}; hence, most studies of these disorders have focused on the CM-intrinsic effects of these genes. However, ~25% of cases are caused by mutations in genes that encode signal transduction components. Genetic analyses and transgenic animal models have confirmed that aberrant signalling can drive pathological cardiac hypertrophy, often in association with other systemic defects^{8–11}.

Abnormal regulation of the RAS/RAF/MEK/ERK (hereafter, RAS/ERK) pathway underlies a group of related developmental syndromes, termed ‘RASopathies’, which are characterized by a spectrum of phenotypes, including craniofacial dysmorphism, delayed growth, cognitive problems and cardiac abnormalities^{12–14}. The most common RASopathy, Noonan Syndrome (NS), can be caused by germ-line gain-of-function *PTPN11*, *KRAS*, *NRAS*, *RRAS*, *SHOC2*, *SOS1/2*, *RAF1*, *RIT1* or *PPP1CB* alleles^{12,15–20}. Pathological LVH (NS-cardiomyopathy) is seen in ~20% of NS cases overall. Kinase-activating mutations in *RAF1*, which encodes a serine/threonine kinase for MEK, account for a small fraction (~5%) of NS, but nearly all (>95%) such patients develop NS-cardiomyopathy²¹. Previously, we found that *Raf1*^{L613V/+} knock-in mice recapitulate the human disorder, with growth defects, facial dysmorphism and most importantly, eccentric LVH²². Specifically, in *Raf1*^{L613V/+} knock-in mice, heart mass, ventricular wall thickness, ventricular chamber dimensions and cardiac contractility are increased, and cardiac fibrosis following pressure overload is exacerbated.

Capitalizing on our inducible *Raf1*^{L613V} allele (*Raf1*^{L613Vfl}) (ref. 22), we deconstructed the above cardiac phenotypes into their contributing cell types. Surprisingly, although expression of mutant *Raf1* in CMs caused altered contractility as a consequence of increased calcium sensitivity, it did not result in pathological LVH. Mutant expression in activated cardiac fibroblasts (CFs) or CMs resulted in an increased fibrotic response to pressure overload. Intriguingly, mutant expression in ECs, by means of a Tumour Necrosis Factor alpha (TNF)/interleukin-6 (IL6) cytokine hierarchy, led to increased CM and chamber size without affecting contractility. Treatment of *Raf1*-mutant mice with anti-TNF antibodies reversed their increased CM size and wall thickness. Our results reveal the cellular and molecular complexity underlying NS-cardiomyopathy and suggest that anti-TNF antibodies could be a therapeutic option for severe pathological LVH in NS patients.

Results

CM-specific *Raf1*^{L613V} expression alters contractility. We crossed *Raf1*^{L613Vfl/+} knock-in mice with lineage-specific Cre recombinase lines, which catalysed ‘STOP’ cassette deletion selectively in the expected cell types (Fig. 1a and Supplementary Fig. 1a). Mutant expression in CMs was achieved using mice expressing Cre under the control of the *Mlc2v* promoter, which is activated efficiently and exclusively in ventricular CMs as early as E8.75 (ref. 23). As anticipated, the ‘STOP’ cassette in the *Raf1*^{L613V} allele had been excised efficiently in the hearts of 10-week-old mice (compare to global *Raf1*^{L613V/+} mice; Supplementary Fig. 1b), as well as in isolated CMs at postnatal day 4 (Supplementary Fig. 1c). Surprisingly, and in stark contrast

to global *Raf1*^{L613V/+} mice, heart weight to body weight (HW/BW) ratio and CM cross-sectional area (CSA) in *Mlc2v*-*L613V* mice were comparable to littermate controls (Fig. 1b,c). Similarly, HW/BW ratio was not increased (and in fact, was slightly decreased) when *Raf1*^{L613V} expression was induced in atrial and ventricular myocardium under the control of the cardiac troponin T promoter²⁴ (Supplementary Fig. 1d). Echocardiography, performed at 16 weeks of age, revealed reduced left ventricular internal end-systolic (LVIDs) and -diastolic (LVIDd) dimensions (Fig. 1d,e) and a small increase in left ventricular posterior wall thickness (LVPWd; Fig. 1f) in *Mlc2v*-*L613V* hearts.

Although *Mlc2v*-*L613V* hearts showed minimal hypertrophy, they were markedly hyper-contractile. As in global *Raf1*^{L613V/+} mice, ejection fraction (EF) and fractional shortening (FS) were increased in *Mlc2v*-*L613V* mice, compared with controls (Supplementary Table 1). Invasive hemodynamics revealed increased $dP/dt_{\max}$ and dP/dt_{LVP40} (Fig. 1g); the latter is independent of the slightly reduced afterload (systolic pressure) observed in these mice (Supplementary Table 2). Thus, CM-restricted *RAF1*-mutant expression induces a hyper-contractile state in the absence of CM hypertrophy.

To ask whether the effects of the *RAF1* mutant on cardiac contractility originated from alterations in Ca^{2+} homeostasis, we loaded CMs isolated from *Mlc2v*-control or -*L613V* mice with Fura-2 and measured Ca^{2+} transients (that is, $R_{340/380}$) in response to field stimulation at 0.5 Hz. Representative Ca^{2+} transients were similar in freshly isolated single *Mlc2v*-control and -*L613V* CMs (Supplementary Fig. 2a). Neither basal Ca^{2+} levels, nor the Ca^{2+} transient peaks, differed between the groups (Supplementary Fig. 2b: basal $R_{340/380}$ was 1.00 ± 0.02 for *Mlc2v*-control versus 1.03 ± 0.02 for *Mlc2v*-*L613V*, $P = 0.24$, two-tailed Student's *t*-test; peak $R_{340/380}$ was 1.82 ± 0.05 for *Mlc2v*-control versus 1.81 ± 0.05 for *Mlc2v*-*L613V*, $P = 0.90$, two-tailed Student's *t*-test). Likewise, no differences were observed in the kinetics of the Ca^{2+} transients (Supplementary Fig. 2c: time to the $R_{340/380}$ peak 47.72 ± 2.57 ms in *Mlc2v*-control versus 46.12 ± 2.36 ms in *Mlc2v*-*L613V*, $P = 0.65$, two-tailed Student's *t*-test; time to 50% decay of the $R_{340/380}$ was 218.17 ± 8.07 ms for *Mlc2v*-control versus 210.62 ± 9.36 ms for *Mlc2v*-*L613V*, $P = 0.55$, two-tailed Student's *t*-test). Quantitative reverse-transcription PCR (qRT-PCR) and immunoblots of lysates from *Mlc2v*-*L613V* hearts showed similar levels of SERCA mRNA and protein, respectively, as in littermate control hearts (Supplementary Figs 2d,e and 9).

Enhanced cardiac contractility in *Mlc2v*-*L613V* mice in the absence of elevated intracellular Ca^{2+} levels might reflect increased Ca^{2+} -sensitivity of the contractile apparatus. We assessed Ca^{2+} sensitivity by determining the relationship between force and Ca^{2+} during twitches induced by field stimulation of isolated CMs attached to stiff glass rods (Supplementary Fig. 3)^{25,26}. Plots of force as a function of Ca^{2+} (phase plots²⁵) during the very late phase of the force relaxation curve became independent of peak force levels when CMs were held at a resting sarcomere length of $1.8 \mu\text{m}$ (Supplementary Fig. 4). Hence, the force- Ca^{2+} relationship achieves a steady state during the terminal phase of relaxation, which enables assessment of the Ca^{2+} sensitivity of CM contractile proteins²⁵. Typical simultaneous force- Ca^{2+} recordings for *Mlc2v*-control and -*L613V* CMs revealed comparable decay kinetics of the Ca^{2+} transient (solid lines) in both groups, but the force in the late phase of relaxation (dashed lines) was elevated markedly in *Mlc2v*-*L613V* CMs, suggesting higher Ca^{2+} sensitivity (Fig. 2a,b). Superimposing the force- Ca^{2+} phase plots for several *Mlc2v*-control and -*L613V* CMs confirmed that the force in mutant CMs was generally above the

Figure 1 | CM-specific *Raf1*^{L613V} expression causes enhanced contractility. (a) Schemes for generating mice with tissue-specific *Raf1*^{L613V} expression and controls (controls are a combination of wild type, *Raf1*^{L613V/+}, and the respective Cre mice, unless indicated otherwise; no significant differences were seen between control groups across all experiments). (b) Representative gross morphology and H&E-stained sections of Mlc2v-L613V and littermate control hearts at week 10 (scale bar, 1 mm). Heart weight to body weight (HW/BW) was measured at 4 months of age (mean ± s.e.m.; *n* = 38 (Mlc2v-control) or 13 (Mlc2v-L613V); statistical significance was assessed using two-tailed Student's *t*-test). (c) Representative wheat germ agglutinin (WGA)-stained cross-sections of hearts from 10-week-old Mlc2v-L613V and control mice (original magnification, × 400; scale bars, 50 μm). Cross-sectional area (right) was quantified using ImageJ (mean ± s.e.m.; *n* = 5 samples per group, with 200 CMs counted per sample; *P* = 0.18, two-tailed Student's *t*-test). (d) Representative echocardiograms of hearts from 4-month-old mice. Arrows indicate LV diastolic dimensions. (e) Left ventricular end-systolic and end-diastolic dimensions (LVIDs and LVIDd, respectively) and (f) Left ventricular posterior wall thickness (LVPWd), measured by echocardiography at 4 months (mean ± s.e.m.; *n* = 43 (Mlc2v-control) or 17 (Mlc2v-L613V); **P* < 0.05, ****P* < 0.001, two-tailed Student's *t*-test). (g) Cardiac contractility of 4-month-old mice, measured by invasive hemodynamics (mean ± s.e.m.; *n* = 39 (Mlc2v-control) or 16 (Mlc2v-L613V). ****P* < 0.0001, two-tailed Student's *t*-test).

force generated by control CMs during the late phase of the twitch relaxation (Fig. 2c,d). The difference between control and mutant CMs is more obvious in Fig. 2e, which shows the force- Ca^{2+} relationship (insets in Fig. 2c,d) on an expanded scale. The force averages at five Ca^{2+} levels for the same Mlc2v-control and -L613V CMs show that mutant CMs develop more force as a function of Ca^{2+} ; that is, that the calcium sensitivity of their contractile proteins is increased (Fig. 2f).

RAF1-mutant CMs and activated fibroblasts increase fibrosis.

The above results imply that (an)other cardiac cell type(s), via paracrine signalling, promotes hypertrophy in RAF1-mutant NS. At baseline, no difference was detected in cardiac morphology or contractile function, save for a slight reduction in LVPWd, in Fsp1-L613V mice, compared with their respective controls (Fig. 3a–d, Supplementary Table 1,2). However, expression of the mutant *Raf1* allele was barely detectable in Fsp1-L613V hearts (Supplementary Fig. 5a), consistent with the greater activity of the Fsp1-Cre line in activated fibroblasts^{27,28}, but making it difficult to reach strong conclusions about the effects of mutant expression in fibroblasts under basal conditions. To gain some insight into this issue, we asked whether RAF1-mutant CFs can promote CM hypertrophy *in vitro*. To this end, we co-cultured CD90⁺ cells from *Raf1*^{L613V/+} global knock-in hearts²² with wild type CMs. Notably, myocyte size was comparable to those co-cultured with

control CD90⁺ cells (Supplementary Fig. 5b); under the same conditions, mutant ECs promote CM hypertrophy *in vitro* (see below).

FSP1 expression is induced in activated cardiac (and other) fibroblasts upon stress (Supplementary Fig. 5a)^{27,28}. Indeed, compared with controls, Fsp1-L613V mice developed more severe interstitial fibrosis within 2 weeks of biomechanical stress imposed by transverse aortic constriction (TAC; Fig. 3e,f). Interestingly, the extent of the fibrotic response did not correlate with a more severe impairment in cardiac function, as EF, FS, $\text{dP/dt}_{\text{max}}$ and $\text{dP/dt}_{\text{LVP40}}$ were comparable in Fsp1-L613V and littermate control mice following TAC (Fig. 3g,h and Supplementary Tables 1,2). FSP1 also is reported to mark hematopoietic and endothelial cells, and endothelial-to-mesenchymal transition (EndoMT) can contribute to cardiac fibrosis^{29,30}. However, Tie2-L613V mice, which direct *Raf1*^{L613V} expression to endocardial/endothelial cells (ECs), did not develop more cardiac fibrosis than controls after TAC, arguing against a pro-fibrotic role for mutant expression in these cells (Fig. 3e,f). We cannot, however, exclude the less parsimonious possibility that dual action in ECs and activated fibroblasts mediates fibrosis in Fsp1-L613V mice.

Enhanced fibrosis also was observed in Mlc2v-L613V hearts in response to TAC (Fig. 3e,f), along with loss of their hypercontractility (Fig. 3g,h and Supplementary Tables 1,2). Conceivably, prolonged pressure overload would lead to further

Figure 2 | Increased Ca^{2+} sensitivity in Mlc2v-L613V hearts. Force- Ca^{2+} relationships measured in single isolated CMs during twitches in response to field stimulation. **(a,b)** Typical Ca^{2+} transients and force measurements for Mlc2v-control **(a)** and -L613V **(b)** myocytes attached to glass rods. Note that during the late phase of relaxation, the force level is much higher in the Mlc2v-L613V CMs compared with controls, despite their similar Ca^{2+} transients. **(c,d)** Superimposed force- Ca^{2+} relationships in response to field stimulation (that is, phase plots²⁵) for several Mlc2v-control **(c)** and -L613V **(d)** CMs. **(e)** Magnified and superimposed force/ Ca^{2+} recordings for Mlc2v-control (black) and -L613V (red) CMs during late phase relaxation, when the relationship between force and Ca^{2+} reaches a steady state (Supplementary Fig. 4). **(f)** Averaged force levels at 5 selected Ca^{2+} levels, showing upward shift of Mlc2v-L613V, compared with control, CMs, indicative of greater force generation for the same Ca^{2+} level (* $P < 0.05$, ** $P < 0.01$, two-tailed Student's *t*-test).

deterioration of cardiac function, and ultimately, functional decompensation, in Mlc2v-L613V mice, as seen in global *Raf1*^{L613V/+} mice at 8 weeks after TAC²². Notably, TAC did not alter the hypertrophic response in Mlc2v-L613V or *Fsp1*-L613V hearts compared to their respective controls (Fig. 3i,j).

EC-specific *Raf1*^{L613V} expression causes cardiac hypertrophy.

By contrast, selective expression of *Raf1*^{L613V} in ECs (achieved by crossing *Raf1*^{L613V/f/+} mice to *Tie2*Cre or *Nfatc1*Cre mice; Supplementary Fig. 1c) was associated with marked cardiac hypertrophy both basally (Fig. 4a,b) and following TAC (Fig. 3i,j), as indicated by significant increases in HW/BW ratio and CM CSA. Cardiac hypertrophy was detectable as early as post-natal day 4 (Supplementary Fig. 6a,b), but there was no difference in the number of BrdU⁺ (proliferation) or TUNEL⁺ (apoptosis) CMs in embryonic Tie2-L613V and *Nfatc1*-L613V hearts (Supplementary Fig. 6c,d). Valvuloseptal development and function were normal, as assessed by histology (Supplementary Fig. 6e) and by the absence of a significant pressure gradient across the aortic valve (Supplementary Table 2). Systemic arterial pressure was lower in Tie2-L613V or *Nfatc1*-L613V mice than in controls (Supplementary Table 2), excluding hypertension as the cause of cardiac hypertrophy. Echocardiograms revealed markedly increased LVIDs and LVIDd (Fig. 4c,d), along with increased

LVPWd (Fig. 4e). Remarkably, contractility remained within normal limits, as assessed by echocardiography and invasive hemodynamic analysis (Fig. 4f and Supplementary Tables 1,2). Even when subjected to TAC, cardiac contractility in Tie2-L613V mice remained comparable to littermate controls (Fig. 3g,h and Supplementary Table 1,2). Hence, hypertrophy, hyper-contractility and fibrosis in global *Raf1*^{L613V/+} mice are separable, and must reflect distinct cellular and molecular mechanisms.

RAF1-mutant ECs induce CM hypertrophy via TNF/IL6 signalling.

Endothelial cells in the heart can influence cardiac development and function via paracrine signals³¹. To explore the non-cell-autonomous effects of endocardium/endothelium on CM hypertrophy, we purified RAF1 mutant or control cardiac ECs with CD31 magnetic beads, and co-cultured them with wild type neonatal CMs in serum-free media conditions (Fig. 5a). Consistent with our *in vivo* findings, CM surface area was increased after 3 days of co-culture with Tie2-L613V or *Nfatc1*-L613V ECs, compared with those co-cultured with controls (Fig. 5b and Supplementary Fig. 7a). RAF1-mutant CMs exhibited similar increases in cell size to control CMs after co-culture with RAF1-mutant ECs, confirming that signals emanating from ECs are the primary cause of CM hypertrophy (Supplementary Fig. 7b). A similar size increase occurred in

Figure 3 | CM- or Fsp1-driven *Raf1*^{L613V} expression enhances fibrosis after TAC. (a–d) Baseline measurements. **(a)** Baseline HW/BW ratio of Fsp1-L613V and control mice at 10 weeks of age. **(b)** Baseline LVIDs and LVIDd and **(c)**, LVPWd, as measured by echocardiography at 4 months (mean ± s.e.m.; $n = 18$ (Fsp1-control); 7 (Fsp1-L613V); * $P < 0.05$, two-tailed Student's t -test). **(d)** Baseline cardiac contractility of 4-month-old mice, measured by invasive hemodynamics (mean ± s.e.m.; $n = 9$ (Fsp1-control) or 5 (Fsp1-L613V); statistical significance was assessed using two-tailed Student's t -test). **(e–j)** measurements at 2 weeks after TAC. **(e)** Interstitial fibrosis in Mlc2v-L613V and Fsp1-L613V hearts, shown by Picro Sirius Red (PSR) staining; original magnification, ×100; scale bars, 100 μm at 2 weeks after TAC. **(f)** Percentage pixels staining positive for interstitial fibrosis with PSR were quantified using ImageJ (mean ± s.e.m.; $n = 9$ (Mlc2v-control), 4 (Mlc2v-L613V), 8 (Fsp1-control), 7 (Fsp1-L613V), 8 (Tie2-control) or 5 (Tie2-L613V); * $P < 0.05$, ** $P < 0.01$, two-tailed Student's t -test). Note that there is no difference between Tie2-L613V and its respective controls. **(g,h)** Cardiac contractility, measured by invasive hemodynamics 2 weeks post TAC (mean ± s.e.m.; $n = 9$ (Mlc2v-control), 4 (Mlc2v-L613V), 9 (Fsp1-control), 8 (Fsp1-L613V), 36 (Tie2-control) or 11 (Tie2-L613V); statistical significance was assessed using two-tailed Student's t -test). Note absence of contractility difference between Mlc2v-L613V and controls following 2 weeks of TAC. **(i)** Cross-sectional area, quantified by using ImageJ (mean ± s.e.m.; $n = 9$ (Mlc2v-control), 4 (Mlc2v-LV), 9 (Fsp1-control), 8 (Fsp1-LV), 11 (Tie2-control) or 5 (Tie2-L613V), with 200 CMs counted per sample; *** $P < 0.0001$, two-tailed Student's t -test). **(j)** HW/BW ratio 2 weeks post TAC (mean ± s.e.m.; $n = 6$ (Mlc2v-control), 2 (Mlc2v-LV), 9 (Fsp1-control), 3 (Fsp1-LV), 17 (Tie2-control) or 4 (Tie2-L613V); * $P < 0.05$, one-tailed Student's t -test).

Transwell assays (Fig. 5a,c), suggesting that (a) diffusible, paracrine factor(s) derived from RAF1-mutant ECs promotes CM hypertrophy.

To search for this paracrine factor(s), we screened conditioned media from Tie2-L613V or control ECs for multiple cytokines, including known inducers of cardiac hypertrophy (Supplementary Fig. 7c). We observed 1.5–2 fold increases in the levels of TNF and IL6 in conditioned media from mutant ECs (Fig. 5d). The *Tnf* promoter contains Activator protein-1 (AP-1) and ETS-1 (transcription factors downstream of ERK) binding sites^{32,33}, and RNAseq analysis revealed increased transcripts of *Tnf* (among other genes) in mutant ECs (Supplementary Fig. 7d). We confirmed this finding by using qRT-PCR (Fig. 5e). By contrast, the increased IL6 production reflected post-transcriptional regulation (Supplementary Fig. 7e). The isolated CD31⁺ population contained almost no CD45⁺ cells (Supplementary Fig. 7f), and heart sections from Tie2-L613V mice exhibited comparable CD45 staining to their littermate controls (Supplementary Fig. 7g), arguing against contaminating

hematopoietic cells as the source of the increased TNF and IL6 in EC-conditioned media.

Addition of recombinant mouse TNF or IL6 (at levels similar to those found in RAF1-mutant EC-conditioned media) induced dose-dependent increases in wild type CM size (Supplementary Fig. 8a,b). Furthermore, neutralizing anti-TNF or anti-IL6 monoclonal antibodies (but not cognate isotype-matched controls) blocked the pro-hypertrophic effects of RAF1-mutant ECs on co-cultured CMs. As expected, the effects of each neutralizing antibody were reversed by adding an excess of the cognate exogenous cytokine (Fig. 5f,g). These data argue that TNF/IL6 produced by mutant cardiac ECs play a critical role in the development of cardiomyopathy in RAF1-mutant NS.

In many inflammatory disorders, most notably, rheumatoid arthritis, TNF stands atop a cytokine hierarchy that can include IL6 (refs 34,35). An analogous hierarchy appears to be present in RAF1-mutant ECs: TNF increased, whereas anti-TNF antibody treatment decreased the levels of IL6 in cardiac EC-conditioned media (Supplementary Fig. 8c). Furthermore, the hypertrophy-

Figure 4 | EC-specific *Raf1*^{L613V} expression causes cardiac hypertrophy. (a) Representative gross morphology and H&E-stained sections of Tie2-L613V and control hearts at 10 weeks (scale bar, 1 mm), and HW/BW of Tie2-L613V and Nfatc1-L613V mice, measured at 4 months (mean $\pm$ s.e.m.; $n = 27$ (Tie2-control), 13 (Tie2-L613V), 15 (Nfatc1-control) or 8 (Nfatc1-L613V); *** $P < 0.0001$, two-tailed Student's t -test). (b) Representative WGA-stained cross-sections of 10-week-old Tie2-L613V and control hearts (original magnification, $\times 400$; scale bars, 50 μ m). Cross-sectional area (right), quantified using ImageJ (mean $\pm$ s.e.m.; $n = 5$ samples per group, with 200 CMs counted per sample; ** $P < 0.005$, * $P < 0.05$, two-tailed Student's t -test). (c) Representative echocardiograms of hearts from 4-month-old mice. Arrows indicate LV diastolic dimensions. (d) LVIDs and LVIDd and (e), LVPWd, measured by echocardiography at 4 months (mean $\pm$ s.e.m.; $n = 24$ (Tie2-control), 12 (Tie2-L613V), 15 (Nfatc1-control) or 9 (Nfatc1-L613V); ** $P < 0.005$, *** $P < 0.001$, two-tailed Student's t -test). (f) Cardiac contractility of 4-month-old mice, measured by invasive hemodynamics (mean $\pm$ s.e.m.; $n = 27$ (Tie2-control), 13 (Tie2-L613V), 15 (Nfatc1-control) or 8 (Nfatc1-L613V); statistical significance was assessed using two-tailed Student's t -test).

reducing effects of the neutralizing anti-TNF antibody were reversed by excess IL6, as well as by TNF, placing IL6 production 'downstream' of TNF stimulation (Fig. 5f). IL6 signals via the IL6 receptor/gp130 complex, which in turn, activates the JAK/STAT, MEK/ERK and PI3K/AKT pathways. Consistent with IL6 acting as the proximate mediator of LVH *in vivo*, immunoblots of total heart extracts from Tie2-L613V mice, which express mutant RAF1 only in ECs but predominantly contain CM-derived proteins, revealed increased activation of STAT3 (phospho (p)-Tyr705) and STAT5 (p-Tyr694), MEK (p-Ser217/221), ERK (p-Tyr204Thr202) and AKT (p-Ser473 and p-Thr308; Fig. 5h, Supplementary Figs 8d–i, 10 and 11), compared with control hearts.

CM hypertrophy is normalized by TNF inhibition *in vivo*. Our co-culture experiments implicated EC-derived TNF in the pathogenesis of CM hypertrophy. We therefore asked if TNF inhibition could normalize EC-induced CM hypertrophy *in vivo*. Tie2-L613V or littermate control mice (4 week-old) were injected intraperitoneal (i.p.) with anti-TNF neutralizing antibody or isotype control (5 mg kg⁻¹ body weight) twice weekly for 6 weeks (Fig. 6a). Ventricular chamber dimensions and HW/BW ratio remained elevated in Tie2-L613V mice after 6 weeks of anti-TNF antibody treatment (Supplementary Fig. 8j–l). However, LVPWd was significantly reduced in hearts from anti-TNF antibody-treated Tie2-L613V mice, compared with isotype control-treated mice (Fig. 6b). We also observed a corresponding decrease in CM CSA in Tie2-L613V mice subjected to TNF inhibition (Fig. 6c). Notably, hearts from wild type littermates were not affected by

anti-TNF antibody treatment, indicating that antibody effects are RAF1 mutant-specific. Furthermore, cardiac function was preserved in Tie2-L613V mice subjected to anti-TNF antibody therapy (Fig. 6d,e). Interestingly, the decreased blood pressure in Tie2-L613V mice also was normalized by anti-TNF treatment (LVP was 97.3 ± 2.4 mm Hg in Tie2-L613V mice with isotype control treatment versus 107.9 ± 0.9 mm Hg in those with TNF inhibition).

Discussion

We find that the combinatorial interactions of CMs, ECs and cardiac fibroblasts underlie the pathogenesis of RAF1-mutant NS-associated cardiomyopathy (Fig. 6f). In line with the conventional view, altered cardiac contractility in this setting arises from a CM-intrinsic defect(s) that causes increased sensitivity of the cardiac contractile apparatus to Ca²⁺. But although CM-specific mutant RAF1 expression slightly increases ventricular wall thickness, the major pro-hypertrophic signals, including TNF (and IL6), emanate from mutant ECs. Moreover, aberrant RAF1 activity in CMs or cardiac fibroblasts, but not ECs, contributes to pressure overload-induced fibrosis in NS-cardiomyopathy.

Our understanding of the role of RAS/ERK pathway in the heart has been based largely on transgenic overexpression or knockout mouse models, typically with a restricted focus on CMs^{36–41}. For example, transient overexpression of a NS-associated *PTPN11* gain-of-function mutation in rat CMs increases Ca²⁺ oscillatory frequency⁴². CMs isolated from a transgenic mouse model of LVH associated with another RASopathy, NS with multiple lentiginos (NS-ML), exhibit

Figure 5 | Cardiac ECs induce cardiomyocyte hypertrophy in vitro. (a) Schematic of direct and transwell co-culture experiments. (b) Neonatal WT CMs were co-cultured for 3 days with CD31⁺ cells from postnatal day 4–7 Tie2-L613V or control hearts. Left: Representative immunofluorescence staining for CD31 (magenta), cardiac troponin T (green) and DAPI (blue) in co-cultures (original magnification, $\times 200$, scale bar, 50 μm). Arrows indicate individual CMs that were among those assessed by ImageJ. Right: Quantification of one of the three independent experiments with similar results. (c) Left: Transwell assays. CD31⁺ cells were seeded in the upper chamber and sizes of neonatal WT CMs (green) in the bottom chamber were assessed using ImageJ (original magnification, $\times 400$, scale bars, 50 μm). Right panel: Quantification of one of three independent experiments with similar results (mean $\pm$ s.e.m.; 300 CMs counted per group; ** $P < 0.005$, *** $P < 0.001$, two-tailed Mann-Whitney test). (d) Conditioned media were collected from CD31⁺ cultures 2 days after a media change, and TNF and IL6 levels were measured by Luminex assay (mean $\pm$ s.e.m.; $n = 4$ each group; ** $P < 0.005$, * $P < 0.05$, two-tailed Student's t -test). (e) *Tnf* mRNA levels in cultured ECs, assessed by qRT-PCR (mean $\pm$ s.e.m.; $n = 4$ each group; ** $P < 0.005$, two-tailed Student's t -test). (f,g) CMs and CD31⁺ cells were co-cultured overnight, and then subjected to either (f) anti-TNF antibody (MP6-XT22, 1 ng ml⁻¹), or (g) anti-IL6 neutralizing antibody (MP5-20F3, 10 ng ml⁻¹) or isotype control (IgG1) in the presence or absence of excess recombinant TNF (1 ng ml⁻¹) or IL6 (25 ng ml⁻¹), as indicated. Quantification is shown for one of three independent experiments with similar results (mean $\pm$ s.e.m.; 300 CMs counted per group; ** $P < 0.005$, *** $P < 0.0001$, Dunn's *post hoc* test when ANOVA (Kruskal-Wallis test) was significant; ## $P < 0.005$, two-tailed Mann-Whitney test). Note that either exogenous TNF or IL6 reverses the inhibitory effect of anti-TNF antibody. (h) Heart lysates from Tie2-L613V or control mice were analysed by immunoblotting with the indicated antibodies. STAT3 and STAT5 levels serve as loading controls.

increased calcium transients and SERCA expression⁴³. CMs derived from *BRAF*-mutant human induced pluripotent cells (hiPSCs) from patients with cardio-facial-cutaneous syndrome also have increased calcium transients⁴⁴. Conversely, we find that a NS-associated activating RAF1 mutant, when expressed solely in CMs, does not affect Ca²⁺ levels, but instead, increases the Ca²⁺ sensitivity of the contractile apparatus. We observe a similar alteration in calcium sensitivity in RAF1-mutant human CMs derived from hiPSCs or ESCs (T. Araki, unpublished observations). Precisely how mutant RAF1 regulates Ca²⁺

sensitivity remains to be elucidated, although it likely involves altered phosphorylation of key calcium handling or myofilament proteins^{45,46}. Taken together, though, these findings suggest that different RASopathy mutations might alter CM contractility in distinct ways.

Surprisingly, mutant RAF1 expression in CM causes minimal hypertrophy. By contrast, EC-restricted mutant expression does not affect contractility, but evokes hypertrophy. Excess TNF produced by mutant ECs can, via a cytokine hierarchy that includes IL6 and probably other agonists, account for their pro-

Figure 6 | Anti-TNF antibody treatment normalizes CM hypertrophy in vivo. (a) Schematic of the treatment regimen. (b) TNF inhibition normalizes LVPWd after treatment for 6 weeks, as assessed by echocardiography (mean $\pm$ s.e.m.; $n = 10$ (Tie2-control + IgG isotype control), 11 (Tie2-control + anti-TNF Ab), 7 (Tie2-L613V + IgG isotype control) or 9 (Tie2-L613V + anti-TNF Ab); $**P < 0.005$, Bonferroni's post-test when ANOVA was significant; $\#P < 0.05$ two-tailed Student's t -test). (c) Representative WGA-stained cross-sections of hearts from treated animals (original magnification, $\times 200$; scale bars, 50 μ m). CSA (right), quantified using ImageJ (mean $\pm$ s.e.m.; $n = 7$ (Tie2-control + IgG isotype control), 9 (Tie2-control + anti-TNF Ab), 7 (Tie2-L613V + IgG isotype control) or 5 (Tie2-L613V + anti-TNF Ab); with 200 CMs counted per sample; $*P < 0.05$, Bonferroni's post-test when ANOVA was significant; $\#P < 0.05$, two-tailed Student's t -test). (d) Ejection fraction and (e) fractional shortening, measured by echocardiography, showing preserved cardiac function following TNF inhibition (mean $\pm$ s.e.m.; $n = 13$ (Tie2-control + IgG isotype control), 15 (Tie2-control + anti-TNF Ab), 9 (Tie2-L613V + IgG isotype control) or 12 (Tie2-L613V + anti-TNF Ab); statistical significance was assessed using ANOVA). (f) Models illustrating how the combined cell-autonomous and non-cell-autonomous actions of activating RAF1 mutants cause NS-cardiomyopathy (see text for details).

hypertrophic effects *in vitro* (that is, co-culture/Transwell assays). Interfering with TNF action (by neutralizing antibody injections) also normalizes the increased ventricular wall thickness and CM size *in vivo*. Reverse remodelling is not complete, however, as chamber size and HW/BW remain elevated. Notably, complete remodelling is possible, as MEK inhibitor treatment fully reverses pathological hypertrophy in global *Raf1*^{L613V/+} mice²².

Failure of anti-TNF therapy to restore normal cardiac chamber size presumably reflects other, TNF-independent, paracrine signals from mutant ECs. Matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases and ADAMs are implicated in pathological cardiac hypertrophy^{47,48}, and several of these are dysregulated in RAF1-mutant ECs (Supplementary Fig. 7d). Although TNF stimulates production of some MMPs, most MMP promoters contain AP-1 and/or PEA3 elements and could be stimulated directly by ERK-catalysed phosphorylation⁴⁷. Alternatively, TNF could have a 'Goldilocks' effect, with too much or too little having deleterious consequences, and our anti-TNF therapy might have been insufficient to restore normal cardiac size. Indeed, increased TNF levels are seen in patients with LVH and other cardiac disorders^{49–55}. However, results from large clinical trials, as well as several case reports, suggest that too much TNF inhibition can lead to dilated cardiomyopathy and/or heart failure^{56–59}. Notably, cardiac function is preserved in our TNF antibody-treated mice. Nevertheless, future studies will be needed to determine the effect of TNF inhibition on all of the paracrine signalling molecules altered in RAF1-mutant ECs and to assess the dose-response relationship between TNF inhibition and cardiac hypertrophy.

Increasing evidence points to the importance of communication between myocytes and non-myocytes in modulating cardiac function and structure under physiological and pathological conditions^{31,60,61}. Although ECs clearly play essential roles in cardiac valve development and disease, including defects associated with RAS/ERK pathway dysregulation^{62,63}, the role of ECs in driving cardiac hypertrophy has been less explored. While our manuscript was in revision, Lauriol *et al.*⁶⁴ reported that NS-ML-associated hypertrophy arises from expression of catalytically impaired SHP2 (*PTPN11*) solely in EC. They observed ventricular thinning and delayed septal closure in developing hearts, which they attributed to increased AKT and decreased FOXO1 and NOTCH1 signalling. Adult NS-ML mice, however, have cardiac hypertrophy⁶⁵, which Lauriol *et al.* suggest might reflect a compensatory response to ventricular thinning during development. Importantly, Tie2-L613V embryos do not exhibit ventricular thinning. Furthermore, it seems unlikely that a developmental defect fully accounts for the cardiac hypertrophy in NS-ML mice, as postnatal rapamycin treatment rescues NS-ML-associated hypertrophy, suggestive of ongoing pro-hypertrophic signalling⁶⁵. Very recently, Josowitz *et al.*⁴⁴ reported that fibroblast-like cells derived from *BRAF*-mutant hiPSCs have pro-hypertrophic effects on hiPSC-derived CMs, via paracrine transforming growth factor β (TGF β) production. Whether mutant CFs promote hypertrophy in the whole organism context remains to be determined, although conceivably, distinct cardiac cell types are responsible for pathological hypertrophy in different RASopathies.

Regardless, our results, along with other recent work^{44,60,64}, argue for a paradigm shift away from the myocyte-centric view of

cardiac development and disease. Aberrant EC signalling is likely a recurring pathogenic mechanism in RASopathy-associated cardiomyopathy, and might well contribute to other genetic or even secondary forms of LVH. Consequently, it will be important to test whether ECs are a/the source of TNF and IL6 in the more common types of pathological LVH. Furthermore, anti-TNF and/or IL6 signalling pathway agents might prove beneficial as targeted therapy for treating RASopathy patients with severe LVH.

Methods

Generation of mice. Mlc2v-L613V, Fsp1-L613V, Tie2-L613V, Nfatc1-L613V and cTnT-L613V mice were generated by crossing inducible *Raf1^{L613V/f/+}* knock-in mice (129Sv × C57BL/6)²² and Mlc2v-Cre²³, Tie2-Cre⁶⁶, Nfatc1-Cre⁶⁷, Fsp1-Cre⁶⁸ or cTnT-Cre²⁴, respectively. Sixteen-week-old male mice were used for all cardiac physiology experiments. For all experiments, investigators were blinded to animal genotype. PCR genotyping was performed as described²²; detailed conditions are available from J.C.Y. All animal studies were approved by the Animal Care Committees of University Health Network and the University of Guelph and were performed in accordance with the standards of the Canadian Council on Animal Care. Based on previous results²², we had 80% power to detect differences of >15% in all cardiac parameters with at least eight mice per group with a significance level of 0.05 (Student's *t*-test).

Echocardiographic and hemodynamic analysis. For echocardiographic and hemodynamic analysis, mice were anaesthetized with isoflurane/oxygen (2%/100%). Echocardiography was performed with the Vevo2100 system (VisualSonics Inc., Toronto, ON, CA) and the MS550D transducer at 40 MHz. Acquired M-mode images were analysed with the LV-trace function from the cardiac package (VisualSonics Inc., Toronto, ON, CA). All measurements were made between 12 and 5 PM. Following echocardiographic assessment, mice were transferred to a warmed surgical plate, maintained at 37 °C using a heating lamp and rectal probe, and a 1.2F catheter (FTS-1211B-0018; Scisense Inc.) was inserted via the right carotid into the LV. Hemodynamic signals were digitized at 2,000 Hz and recorded using iWorx analytic software (LabScribe2, Dover, NH, USA). Following data collection, mice were sacrificed by cardiac excision.

Primary cell isolation and culture. Adult ventricular CMs were isolated from male Mlc2v-control or -L613V mice between 2 and 5 months of age. After heparin was administered i.p. (10 IU g⁻¹ body weight), mice were deeply anaesthetized with isoflurane, and their hearts were removed and placed in ice-cold modified Ca²⁺-free Tyrode's solution (pH 7.3). Excised hearts were perfused with the same solution at 37 °C for 8 min, after which type II collagenase (88 U ml⁻¹, Worthington Biochemical Corporation) plus pure Yakult Collagenase (125 U ml⁻¹, Yakult Pharmaceutical Industry Corporation) were introduced for 10–12 min. The inner layer of the left ventricle was removed into a Ca²⁺-free Tyrode's solution, gently cut into small pieces, and triturated using a polished glass pipette. Dissociated CMs were allowed to settle for 5 min in a 50 ml conical tube, the supernatant was discarded to remove residual enzyme, and the CMs were re-suspended. This settling/resuspension sequence was repeated twice. Isolated CMs were stored at room temperature (25 °C) until use.

To isolate neonatal CMs, single-cell suspensions were prepared using the Neonatal Heart Dissociation Kit (Miltenyi Biotec), according to the manufacturer's instructions. Non-myocytes were depleted by magnetic activated cell sorting (MACS; Miltenyi Biotec).

For non-myocyte isolation, postnatal day 4–7 hearts were minced into small pieces. Single-cell suspensions were prepared by enzymatic digestion with collagenase (300 U ml⁻¹) and hyaluronidase (100 U ml⁻¹) from STEMCELL Technologies Inc. for 45 min with gentle rotation, followed by mechanical dissociation. ECs and fibroblasts were enriched by MACS using CD31 and CD90 microbeads, respectively.

Isolated neonatal CMs or postnatal non-myocytes were plated onto 2% gelatin-coated 96-well plates (day 0), and maintained or co-cultured in StemPro-34 media (Life Technologies) supplemented with rhbFGF (5 ng ml⁻¹; R&D) and rhVEGF (20 ng ml⁻¹; Cedarlane). For dose-response assays, wild type CMs were treated with mouse recombinant TNF or IL6 (ThermoFisher) for 3 days at the indicated doses. Co-cultured cells were washed with HBSS once before a media change on day 1, at which point cells were subjected to neutralizing antibody treatments, as indicated. For Transwell assays, CMs were plated on the gelatin-coated bottoms of the Transwell system (Corning Costar), and CD31⁺ cells were plated onto collagen-coated membrane inserts.

Measurement of Ca²⁺ transients. Aliquots of freshly isolated ventricular CMs were placed in a storage solution containing 1 μM Fura-2-acetoxymethyl ester (AM) for 20 min at room temperature (25 °C), after which the cells were dispersed onto a glass-bottomed chamber equipped with platinum electrodes to allow field stimulation. After 3 min, myocytes were washed for 5 min with a modified Krebs–

Henseleit perfusion solution (120 mM NaCl, 5.4 mM KCl, 1 mM MgCl₂, 10 mM HEPES, 10 mM glucose, 19 mM NaHCO₃, 1.2 mM CaCl₂ and 1 mM Na pyruvate; pH 7.3). Fura-2 fluorescence was measured by illuminating CMs via the rear light port of an Olympus 1 × 70 microscope, alternating every 10 s between 340 and 380 nm light (10 nm band-pass) originating from a 75 W xenon arc lamp. The light was projected to the CMs by a 40 × objective (UAp0/340, 40 × /0.9NA, Olympus). The emitted light at 510 nm (± 20 nm) from the CMs was projected onto an Evolve 128 camera (Photometrics) and acquired at 100 frames/s via Metamorph software (molecular devices). Images were analysed using ImageJ. Field stimulation was applied for 5 min at 0.5 Hz, using 2 ms pulses at twice the threshold voltage (typically 10 V cm⁻¹). Only rod-shaped CMs displaying clear striation patterns and stable shortening patterns were used for Ca²⁺ transient recordings. To determine basal auto-fluorescence, a Krebs's–Henseleit solution containing 2 mM Mn²⁺ (and no Ca²⁺) was applied, which quenches the Fura-2 fluorescence signal. Ca²⁺ transients were quantified by the equation:

$$R_{340/380} = \left(F_{340} - F_{340}^{\text{background}} \right) / \left(F_{380} - F_{380}^{\text{background}} \right) \quad (1)$$

where F_{340} and F_{380} are the intensities of the 510 nm fluorescence originating from the Fura-2 in the CMs when illuminated with light at 340 nm and 380 nm, respectively. $F_{340}^{\text{background}}$ and $F_{380}^{\text{background}}$ are the fluorescence levels measured in the same region of the CMs after Mn²⁺ addition.

Measurement of force and force-Ca²⁺ relationships. Freshly isolated ventricular CMs were loaded with Fura-2 as described above. CMs were attached to a pair of glass rods using the biocompatible adhesive MyoTak (World Precision Instruments, Inc.), as per the manufacturer's directions. After 'adhesion', CMs were lifted from the glass and were field stimulated at various rates (0.1–10 Hz) using 2 ms pulses at twice the threshold voltage (typically 10 V cm⁻¹). During recording of force and Ca²⁺ transients myocytes were illuminated using red light (650–690 nm). Light (510 nm plus 650–690 nm) was collected with a 40 × objective (UAp0/340, 40 × /0.9NA, Olympus) on a 1 × 70 Olympus microscope and projected through a dichroic mirror, which reflected the 510 nm light to the photometrics camera and passed the red light to the a MyocamS Camera (IonOptix). Force is measured as pixels of deflection of the glass rods arising from CM contraction in response to field stimulation. The force was normalized to CM CSA, which was determined at the end of the experiment by imaging each cell with its long axis aligned with the optical axis of the microscope. This approach allows the width and thickness of CMs to be measured accurately. CSA was estimated using the equation $\pi \times 1/2 \text{width} \times 1/2 \text{thickness}$, as suggested⁶⁹. The images of the cells generated by the red light were also analysed by fast Fourier-transforming selected regions of the CMs. This algorithm allows sarcomere length to be rapidly estimated during contractions. Force (in pixels) and Ca²⁺ ($R_{340/380}$) were recorded while keeping the diastolic sarcomere length of the CMs at 1.8 μm.

Transverse aortic constriction. Mice (8–9 week-old, 24–32 g) were anaesthetized with isoflurane/oxygen (2%:100%), intubated, and ventilated (Harvard Apparatus) at 150–180 breaths per min, 250 μl per breath. The transverse aorta was constricted with a 7/0 silk suture tied around a 27-gauge needle, as described²². Pressure overload was maintained for 2 weeks. Mice were housed on a 12-hour light/dark cycle (8am/8pm) and monitored twice daily.

Cytokine measurements. Conditioned media were collected from cultured cells 2 days after a media change and immediately stored at –80 °C until analysis. Luminex bead-based multiplex cytokine arrays (Millipore) were performed in magnetic plates, according to the manufacturer's instructions, and read with a Luminex 100 Reader. Data were analysed using Bio-plex Manager 6.0. IL6 levels following anti-TNF antibody treatment were assessed using a commercially available ELISA (Sigma), according to the manufacturer's instructions. All assays were performed in duplicate.

qRT-PCR. Tissues were flash frozen in liquid nitrogen, and cells were washed with ice-cold HBSS before extraction with QIAzol lysis reagent (Qiagen). RNA was isolated using miRNeasy (Qiagen), according to the manufacturer's instructions. cDNA was synthesized by reverse transcription using oligo (dT) primers and the Superscript III First Strand Synthesis System (Invitrogen). Transcripts were detected and quantified by qRT-PCR using the QuantiFast SYBR Green PCR Kit (Qiagen). Primer sequences are provided in Supplementary Table 3. All values were normalized to *Gapdh* levels.

RNA sequencing. RNA (150 ng) from each sample was reversed transcribed using the Illumina TruSeq Stranded mRNA kit. cDNA libraries were sized on an Agilent Bioanalyzer, and their concentrations were validated by qPCR. Four different libraries were normalized to 10 nM and pooled, 8 pm of pooled libraries were loaded onto an Illumina cBot for cluster generation, and the flow cell was subjected to 100 cycles of paired-end sequencing on an Illumina HighSeq 2000. Normalized and pooled together, and loaded onto Illumina cBot for cluster generation. Pair-end sequencing (100 cycles) was performed on an Illumina HiSeq 2000. The raw

sequence data, in the form of FASTQ files, was aligned to the mouse genome (UCSC mm10, iGenome GTF definition file) using the BOWTIE/TOPIHAT pipeline (BOWTIE v2.2.3, TOPIHAT 2.0.13). Accessory programs for the alignment stage include cutadapt (1.7.1). Transcripts were assembled and gene expression levels were estimated with Cufflinks (v2.2.1) using iGenome GTF file. Cufflinks output result was load into R (3.1.1)/cummeRbund (2.6.1) for final output of results and graphing.

Histology. Hearts were collected in the relaxed state by perfusion-fixation with 1% KCl in PBS, followed by 10% buffered formalin overnight. Staining with H&E, Picro Sirius Red (PSR; 500 ml of saturated picric acid solution and 0.5 g of Direct Red 80 from Sigma-Aldrich) and Masson-trichrome was performed on paraffin-embedded sections (5 µm), according to standard practice. FITC-conjugated wheat germ agglutinin (WGA; Sigma-Aldrich) was used with appropriate antibodies and DAPI for the approximation of CSA in CMs with centrally located nuclei (~200 per sample). ImageJ software was used for quantification. For BrdU incorporation assays, pregnant mice at E16.5 were subjected to BrdU i.p. injection (100 µg g⁻¹ body weight) 1 h before killed. Embryos were fixed overnight in 10% buffered formalin and embedded in paraffin. Sections were stained with primary antibodies against BrdU (1:50 Abcam), followed by secondary antibodies conjugated with F(ab)2 biotin (1:500; Research Diagnostics Inc.), and developed using the Vectastain Elite ABC Kit (Vector Laboratories). All sections were counterstained with hematoxylin. BrdU-positive cells were counted in 20 randomly selected fields from each sample.

For immunofluorescence staining of primary cultures, cells were washed with 1% KCl in ice-cold PBS three times before fixation with 4% paraformaldehyde for 15 min. Cells were stained with 5 µg ml⁻¹ monoclonal rat anti-mouse CD31 antibody (Clone MEC13.3; BD Pharmingen) or 5 µg ml⁻¹ monoclonal rat anti-mouse CD90 antibody (Clone 30-H12; Biolegend) and, after permeabilization with 1% Triton × -100, 2 µg ml⁻¹ monoclonal mouse anti-mouse cTnT antibody (Clone 13-11; Thermo Scientific) and DAPI. Primary antibody binding was visualized by using fluorescence-coupled anti-rat or anti-mouse secondary antibodies (1:250). Images were taken by scanning across the well, with all visualized CMs (at least 300) counted per well.

Immunoblotting. Hearts from 10 to 16-week-old mice were collected and flash frozen in liquid nitrogen. For Ca²⁺ handling proteins, total protein extracts from hearts were prepared by homogenization in 1% SDS (50 mM Tris-HCl, pH 8, 100 mM NaCl, 2 mM EDTA). For signalling proteins, total protein extracts from hearts were prepared by homogenization in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% Na deoxycholate, and 0.1% SDS), containing a protease and phosphatase inhibitor cocktail (40 µg ml⁻¹ PMSF, 20 mM NaF, 1 mM Na₃VO₄, 10 mM β-glycerophosphate, 10 mM sodium pyrophosphate, 2 µg ml⁻¹ antipain, 2 µg ml⁻¹ pepstatin A, 20 µg ml⁻¹ leupeptin and 20 µg ml⁻¹ aprotinin). Lysates were centrifuged at 16,100g for 15 min at 4 °C. Clarified supernatants (70 µg for detection of pSTAT3 and pSTAT5; 10–25 µg for others) were resolved by SDS-PAGE and analysed by immunoblotting. Antibodies used for immunoblots included: anti-ERK2 (7 ng ml⁻¹, Clone D-2; Santa Cruz Biotechnology Inc.), and anti-SERCA2 (Clone D51B11; #9580), anti-phospho-p44/42 MAPK (#9101), -phospho-MEK1/2 (#9121), -phospho-AKT (S473, #9271), -phospho-AKT (T308, Clone 244F9, #4056), -AKT1 (Clone C73H10, #2938), -STAT3 (#9132), -phospho-STAT3 (Y705, #9131), -STAT5 (#9163), -phospho-STAT5 (Y694, #9351; all at 1:1,000 dilutions from Cell Signalling Technology). Primary antibodies were visualized by IRDye infrared secondary antibodies (1:15,000 dilution for 680LT anti-mouse IgG and 1:10,000 dilution for 800CW anti-rabbit IgG), using the Odyssey Infrared Imaging System (LI-COR Biosciences). Immunoblot signals were quantified by using Odyssey version 3.0 software.

Flow cytometry. CD31⁺ cells were stained with 2 µg ml⁻¹ PE-conjugated anti-mouse CD31 antibody (Clone MEC13.3; BD Pharmingen) and 2 µg ml⁻¹ APC-conjugated anti-mouse CD45 antibody (Clone 30F11; BioLegend) and analysed on a LSR II flow cytometer (BD Bioscience). Flow cytometric data were analysed with FlowJo software (TreeStar).

Anti-TNF neutralizing antibody experiments. LEAF purified anti-mouse TNF antibody (MP6- × T22, BioLegend) or LEAF purified rat IgG1 isotype control (RTK2071, BioLegend) was injected i.p. (5 mg kg⁻¹ body weight) twice weekly for the indicated times.

Statistical analysis. All experiments were performed on biological replicates unless otherwise specified. The number of biological replicates is represented by 'n'. Sample size for each experimental group/condition is reported in the appropriate figure legends and methods. For cell culture experiments, sample size was not pre-determined, and all samples were included in analysis. All data are presented as mean ± s.e.m. For normally distributed data, differences between two groups were evaluated by Student's *t*-test and differences between multiple groups were evaluated by ANOVA, followed by Bonferroni's post-test. For non-normally distributed data (Fig. 5b,c,f and g), differences between two groups were evaluated

with the non-parametric Mann–Whitney test and differences between multiple groups were evaluated by the non-parametric Kruskal–Wallis one-way analysis of variance (ANOVA), followed by Dunn's *post hoc* test. For all experiments, except for cell culture experiments (Fig. 5b,c,f and g), the between-group variances were similar and data were symmetrically distributed. All analyses and graphs were generated with GraphPad Prism 5. A *P* value of <0.05 was considered significant.

Data availability. The raw RNAseq data have been deposited in GEO under accession code GSE95739. All other data supporting the findings of this study are available from the corresponding authors on request.

References

- Maron, B. J. & Maron, M. S. Hypertrophic cardiomyopathy. *Lancet* **381**, 242–255 (2013).
- Maron, B. J. Hypertrophic cardiomyopathy: a systemic review. *JAMA* **287**, 1308–1320 (2002).
- Frey, N., Luedde, M. & Katus, H. A. Mechanisms of disease: hypertrophic cardiomyopathy. *Nat. Rev. Cardiol.* **9**, 91–100 (2011).
- Drazner, M. H. The progression of hypertensive heart disease. *Circulation* **123**, 327–334 (2011).
- Seidman, J. G. & Seidman, C. The genetic basis for cardiomyopathy. *Cell* **104**, 557–567 (2001).
- Rader, F., Sachdev, E., Arsanjani, R. & Siegel, R. J. Left ventricular hypertrophy in valvular aortic stenosis: mechanisms and clinical implications. *Am. J. Med.* **128**, 344–352 (2015).
- Alcalai, R., Seidman, J. G. & Seidman, C. E. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. *J. Cardiovasc. Electrophysiol.* **19**, 104–110 (2008).
- Rohini, A., Agrawal, N., Koyani, C. N. & Singh, R. Molecular targets and regulators of cardiac hypertrophy. *Pharmacol. Res.* **61**, 269–280 (2010).
- Heineke, J. & Molkentin, J. D. Regulation of cardiac hypertrophy by intracellular signalling pathways. *Nat. Rev. Mol. Cell Biol.* **7**, 589–600 (2006).
- Dorn, 2nd G. W., Force, T. & Li, G. W. D. Protein kinase cascades in the regulation of cardiac hypertrophy. *J. Clin. Invest.* **115**, 527–537 (2005).
- Sala, V. & Gallo, S. Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. *Mol. Med.* **18**, 1 (2012).
- Tidymann, W. E. & Rauen, K. A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. *Curr. Opin. Genet. Dev.* **19**, 230–236 (2009).
- Rauen, K. A. The RASopathies. *Annu. Rev. Genomics Hum. Genet.* **14**, 355–369 (2013).
- Gelb, B. D. & Tartaglia, M. RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it. *J. Clin. Invest.* **121**, 844–847 (2011).
- Cirstea, I. C. *et al.* A restricted spectrum of NRAS mutations causes Noonan syndrome. *Nat. Genet.* **42**, 27–29 (2009).
- Flex, E. *et al.* Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. *Hum. Mol. Genet.* **23**, 4315–4327 (2014).
- Cordeddu, V. *et al.* Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. *Nat. Genet.* **41**, 1022–1026 (2009).
- Yamamoto, G. L. *et al.* Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. *J. Med. Genet.* **52**, 413–421 (2015).
- Chen, P.-C. *et al.* Next-generation sequencing identifies rare variants associated with Noonan syndrome. *Proc. Natl Acad. Sci. USA* **111**, 11473–11478 (2014).
- Gripp, K. W. *et al.* A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles noonan syndrome with loose anagen hair. *Am. J. Med. Genet.* **170A**, 2237–2247 (2016).
- Pandit, B. *et al.* Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. *Nat. Genet.* **39**, 1007–1012 (2007).
- Wu, X. *et al.* MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation. *J. Clin. Invest.* **121**, 1009–1025 (2011).
- Chen, J., Kubalak, S. W. & Chien, K. R. Ventricular muscle-restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. *Development* **125**, 1943–1949 (1998).
- Jiao, K. *et al.* An essential role of Bmp4 in the atrioventricular septation of the mouse heart service an essential role of Bmp4 in the atrioventricular septation of the mouse heart. *Genes Dev.* **17**, 2362–2367 (2003).
- Backx, P. H., Gao, W. D., Azan-Backx, M. D. & Marban, E. The relationship between contractile force and intracellular [Ca²⁺] in intact rat cardiac trabeculae. *J. Gen. Physiol.* **105**, 1–19 (1995).
- Kentish, J. C. & Wrzosek, A. Changes in force and cytosolic Ca²⁺ concentration after length changes in isolated rat ventricular trabeculae. *J. Physiol.* **506**, 431–444 (1998).
- Iwano, M. *et al.* Evidence that fibroblasts derive from epithelium during tissue fibrosis. *J. Clin. Invest.* **110**, 341–350 (2002).

28. Moore-morris, T. *et al.* Resident fibroblast lineages mediate pressure overload—induced cardiac fibrosis. *J. Clin. Invest.* **124**, 1–14 (2014).
29. Kong, P., Christia, P., Saxena, A., Su, Y. & Frangogiannis, N. G. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. *Am. J. Physiol. Heart Circ. Physiol.* **305**, H1363–H1372 (2013).
30. Zeisberg, E. M. *et al.* Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. *Nat. Med.* **13**, 952–961 (2007).
31. Brutsaert, D. L. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. *Physiol. Rev.* **83**, 59–115 (2003).
32. Newell, C. L., Deisseroth, A. B. & Lopezberestein, G. Interaction of nuclear proteins with an Ap-1 Cre-like promoter sequence in the human *Tnf*- α gene. *J. Leukoc. Biol.* **56**, 27–35 (1994).
33. Kramer, B., Wiegmann, K. & Kronke, M. Regulation of the human *TNF* promoter by the transcription factor Ets. *J. Biol. Chem.* **270**, 6577–6583 (1995).
34. Feldmann, M. & Maini, R. N. Anti-TNF (α) therapy or rheumatoid arthritis: What have we learned? *Annu. Rev. Immunol.* **19**, 163–196 (2001).
35. Neurath, M. F. Cytokines in inflammatory bowel disease. *Nat. Rev. Immunol.* **14**, 329–342 (2014).
36. Hunter, J. J. *et al.* Nucleic acids, protein synthesis, and molecular genetics: ventricular expression of a MLC-2v- *ras* fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice ventricular expression of a MLC-2v- *ras* fusion gene induces. *J. Biol. Chem.* **270**, 23173–23178 (1995).
37. Purcell, N. H. *et al.* Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy *in vivo*. *Proc. Natl Acad. Sci.* **104**, 14074–14079 (2007).
38. Harris, I. S. *et al.* Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. *Circulation* **110**, 718–723 (2004).
39. Zheng, M. *et al.* Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. *Am. J. Physiol. Heart Circ. Physiol.* **286**, H424–H433 (2004).
40. Bueno, O. F. *et al.* The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. *EMBO J.* **19**, 6341–6350 (2000).
41. Yamaguchi, O. *et al.* Cardiac-specific disruption of the *c-ras*-1 gene induces cardiac dysfunction and apoptosis. *J. Clin. Invest.* **114**, 937–943 (2004).
42. Uhlen, P. *et al.* Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. *Proc. Natl Acad. Sci.* **103**, 2160–2165 (2006).
43. Clay, S. A., Domeier, T. L., Hanft, L. M., McDonald, K. S. & Krenz, M. Elevated Ca^{2+} transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines. *Am. J. Physiol. Heart Circ. Physiol.* **308**, 1086–1095 (2015).
44. Josowitz, R. *et al.* Autonomous and non-autonomous defects underlie hypertrophic cardiomyopathy in BRAF-mutant hiPSC-derived cardiomyocytes. *Stem Cell Rep.* **7**, 355–369 (2016).
45. Layland, J., Solaro, R. J. & Shah, A. M. Regulation of cardiac contractile function by troponin I phosphorylation. *Cardiovasc. Res.* **66**, 12–21 (2005).
46. Yuan, C. & Solaro, R. J. Myofilament proteins: from cardiac disorders to proteomic changes. *Proteomics Clin. Appl.* **2**, 788–799 (2008).
47. Spinale, F. G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. *Physiol. Rev.* **87**, 1285–1342 (2007).
48. Olivetti, G., Capasso, J. M., Sonnenblick, E. H. & Anversa, P. Side-to-Side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. *Circ. Res.* **67**, 23–34 (1990).
49. Högye, M., Mándi, Y., Csanády, M., Sepp, R. & Buzás, K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor- α in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. *Am. J. Cardiol.* **94**, 249–251 (2004).
50. Patel, R. *et al.* Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. *J. Mol. Cell Cardiol.* **32**, 2369–2377 (2000).
51. Velten, M. *et al.* Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice. *Cardiovasc. Res.* **96**, 422–432 (2012).
52. Bautista, L. E., Vera, L. M., Arenas, I. A. & Gamarra, G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF- α) and essential hypertension. *J. Hum. Hypertens.* **19**, 149–154 (2005).
53. Vázquez-Oliva, G., Fernández-Real, J. M., Zamora, A., Vilaseca, M. & Badimón, L. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. *J. Hum. Hypertens.* **19**, 457–462 (2005).
54. Lee, D. L. *et al.* Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. *Am. J. Physiol. Heart Circ. Physiol.* **290**, H935–H940 (2006).
55. Levine, B., Kalman, J., Mayer, L., Fillit, H. M. & Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. *N. Engl. J. Med.* **323**, 236–241 (1990).
56. Mann, D. L. *et al.* Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). *Circulation* **109**, 1594–1603 (2004).
57. Rocha, F. A. C. & Silva, F. S. Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis. *J. Clin. Rheumatol.* **16**, 81–82 (2010).
58. Ma, K., Dormand, H., Neyses, L. & Ma, M. Heart failure with etanercept therapy: a case report. *J. Clin. Exp. Cardiol.* **4**, 3–5 (2013).
59. Emmert, M. Y. *et al.* Severe cardiomyopathy following treatment with the tumour necrosis factor- α inhibitor adalimumab for Crohn's disease. *Eur. J. Heart Fail.* **11**, 1106–1109 (2009).
60. Tian, Y. & Morrissey, E. E. Importance of myocyte-nonmyocyte interactions in cardiac development and disease. *Circ. Res.* **110**, 1023–1034 (2012).
61. Takeda, N. & Manabe, I. Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. *Int. J. Inflam.* **2011**, 535241 (2011).
62. Gitler, A. D. *et al.* Nf1 has an essential role in endothelial cells. *Nat. Genet.* **33**, 75–79 (2003).
63. Araki, T. *et al.* Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. *Proc. Natl Acad. Sci. USA* **106**, 4736–4741 (2009).
64. Lauriol, J. *et al.* Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines. *J. Clin. Invest.* **126**, 2989–3005 (2016).
65. Marin, T. M. *et al.* Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome – associated PTPN11 mutation. *J. Clin. Invest.* **121**, 1026–1043 (2011).
66. Koni, P. A. *et al.* Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. *J. Exp. Med.* **193**, 741–754 (2001).
67. Wu, B. *et al.* Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial VEGF signaling. *Cell* **151**, 1083–1096 (2012).
68. Bhowmick, N. A. *et al.* TGF- β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* **303**, 848–851 (2004).
69. King, N. M. P. *et al.* Mouse intact cardiac myocyte mechanics: cross-bridge and titin-based stress in unactivated cells. *J. Gen. Physiol.* **137**, 81–91 (2010).

Acknowledgements

We thank Drs G. Keller, M. Sherrid, G. Fishman and M. Feldmann for the helpful comments, L. Morikawa and N. Law for assistance with histology, J. Tsao, Z. Lu and C. Virtanen for the help with RNAseq, A. Sayad for other statistical analyses, and B. Gurbaksh and P. Yao for the help with Luminex bead-based cytokine array analysis. This work was supported by R01 HL 083273 (B.G.N.) and Canadian Institutes of Health Research grants MOP111159 (J.A.S.) and 106526 to (T.A.) and MOP-83453 to (P.H.B.). B.G.N. was a Canada Research Chair, Tier 1, and work in his laboratory was supported by the grants from the Ontario Ministry of Health and Long Term Care and The Princess Margaret Cancer Foundation. J.A.S. is a new investigator with the Canadian Heart and Stroke Foundation, and J.C.Y. was supported by a CIHR CGS-D scholarship.

Author contributions

B.G.N., X.W., J.A.S. and T.A. conceived the project. B.G.N., T.A., P.H.B. and J.A.S. supervised the research. J.C.Y., P.H.B., T.A., J.A.S. and B.G.N. designed the experiments. J.C.Y., M.J.P., X.T., X.W. and J.A.S. performed the experiments. All authors participated in data analysis. J.C.Y. and B.G.N. wrote the manuscript with the help of all of the authors.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Yin, J. C. *et al.* Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in *RAF1*-mutant Noonan syndrome. *Nat. Commun.* **8**, 15518 doi: 10.1038/ncomms15518 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>